Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKF-INS(A) biosimilar insulin aspart PK/PD similarity study
NCT06492226Phase 1Completed
- Sponsor
- Xentria
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of human insulin in diabetes mellitus (DM) (3 arms), sponsored by Xentria. Primary endpoints: Area Under the Insulin Aspart Concentration-Time Curve From 0 to 12 Hours, Maximum Observed Insulin Aspart Concentration at 12 hours and 2 more. Started Jul 2024; status: completed.
02
Drugs
human insulin
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT06492226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492226.